GPRC5D x CD3 TCE
Multiple myeloma
Key Facts
About Integral Molecular
Integral Molecular is a privately held, revenue-generating biotechnology company that has established itself as an industry leader in membrane protein and antibody discovery technologies. The company operates a dual business model, providing fee-for-service research tools and reagent platforms while also developing its own preclinical therapeutic antibody pipeline for out-licensing. Its core strength lies in tackling difficult membrane protein targets, which are implicated in a wide range of diseases but have been historically challenging for drug discovery. Recent milestones include FDA qualification progress for its Membrane Proteome Array and the advancement of several bispecific and antibody-drug conjugate candidates into preclinical development.
View full company profileTherapeutic Areas
Other Multiple myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| PRG1801 (Anti-BCMA CAR-T) | Pregene Biopharma | Phase 1 |
| CAR-NK Therapy | Pregene Biopharma | Phase 1 |
| Tasquinimod | Active Biotech | Preclinical |
| BCMA CAR-T | Simnova Biotherapeutics | Phase 1 |
| BCMA panCAR (via Orna partnership) | Simnova Biotherapeutics | Preclinical |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| Kyprolis® (carfilzomib) | Cleo Life Sciences | Approved |
| inobrodib (CCS1477) | CellCentric | Phase 1/2 |
| ISB 2001 | Ichnos Glenmark Innovation | Phase 1b |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Hemady | Dexcel Pharma USA | Approved |
| AV-353 | AVEO Oncology | Pre-clinical |